Exagen

www.AviseTest.com

Patient-focused, discovery-driven life sciences company delivering advanced AVISE® autoimmune tests that help support diagnosis, prognosis, and monitoring of lupus and other complex autoimmune diseases. AVISE provides advanced clinical tools for the
Diagnosis, Prognosis & Monitoring of
Autoimmune Connective Tissue Diseases such as, Rheumatoid Arthritis, Lupus, Sjögren’s & Mixed Connective Tissue Disease among others.

03/16/2026

Autoimmune Awareness Month spotlight: Systemic Lupus Erythematosus (SLE) and lupus nephritis

Lupus nephritis occurs when immune complexes deposition and complement activation occur in the kidney, causing glomerular inflammation that can lead to scarring, reduced kidney function, and in some cases, kidney failure. Early disease can be silent.

According to the American College of Rheumatology (ACR):
- Close to half of SLE patients develop lupus nephritis
- Up to 30% mortality at 10 years
- 10–22% progress to end-stage kidney disease (ESKD)

Earlier diagnosis can help prevent irreversible organ damage and improve patient outcomes.

03/11/2026

Autoimmune Awareness Month spotlight: Sjögren’s disease.

Sjögren’s disease can present with fatigue, joint pain, neuropathy, and systemic organ involvement—not just dry eyes or dry mouth. Because symptoms may affect multiple body systems and do not always appear all at once, the broader clinical picture can be easy to miss.

That missed connection has consequences. The Sjögren’s Foundation reports an average of about 3 years from symptom onset to diagnosis, with many patients seeing multiple providers before the disease is recognized.

Sjögren’s disease also frequently overlaps with other autoimmune conditions, yet early diagnosis and management still do not receive the attention they deserve. As the treatment landscape continues to evolve, timely and accurate diagnosis becomes even more important.

We can do better. Recognizing Sjögren’s disease beyond sicca syndrome features, pursuing appropriate diagnostic evaluation when the clinical picture warrants it, and referring promptly are practical steps that may help shorten the path to diagnosis.

Sjögren’s disease is common. Systemic. Treatable. And still too often overlooked.

Learn more about AVISE® CTD and how Exagen is working to help shorten the gap to diagnosis through innovation, education, and clinically informed testing.

03/04/2026

March is Autoimmune Awareness Month, and a reminder that symptoms are often easy to miss.

There are 100+ autoimmune conditions—from rheumatoid arthritis and lupus to multiple sclerosis and type 1 diabetes. Many overlap in symptoms, and getting to a clear diagnosis can take years. ~50 million Americans are estimated to be living with an autoimmune condition.

Awareness supports earlier recognition, more research, and better tools for patients and clinicians.

This month, we’ll share weekly posts on the realities of complex autoimmune presentations, and how AVISE® CTD can help physicians move from early symptoms to more confident diagnostic decisions.

10/16/2025

We look forward to hearing Andrea Fava, MD, present his groundbreaking research, "Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis" at ACR Convergence 2025.

This 15-minute Plenary Talk will highlight novel biomarkers with the potential to enhance early detection and improve management of lupus nephritis.

📍Session Details:
• Location: McCormick Place, Lower Level, Exhibit Hall F2
• Date & Time: October 27th, 2025, 6:30-6:45 AM

🎤 Presentation Title:
• Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis

10/15/2025

We're honored to host an Innovation Theater Presentation at ACR Convergence 2025. Join us as we explore the science shaping the future of autoimmune diagnostics.

📍 Event Details
• Location: McCormick Place Convention Center | Chicago, IL
• Date & Time: Monday, October 27 | 2:30-3:15 PM CDT
• Theater: Innovation Theater A

🎤 Presentation Title:
AVISE® CTD: A Decade of Validation Driving Lupus Diagnostic Accuracy, Seronegative RA Biomarker Innovation, and Novel T Cell Biomarkers for Lupus.

🗣️ Featured Speakers:
• Alvin Wells, MD, PhD, FACP, FACR
• Vasileios Kyttaris, MD, PhD, FACR

We look forward to sharing new insights that continue to advance lupus and rheumatoid arthritis diagnosis and patient care.

10/14/2025

Exagen is proud to announce that we will be attending and presenting at ACR Convergence 2025 in Chicago from October 24-29.

📍 Stop by booth #1228 to learn how we're leading the science of autoimmune disease diagnostics.
At Exagen, our mission is simple: to improve the lives of patients suffering from autoimmune diseases by delivering innovative, trusted diagnostic solutions that empower physicians with clarity and confidence.

We look forward to connecting with the rheumatology community, sharing our latest advancements, and discussing how together we can help drive earlier, more accurate diagnoses and better patient outcomes.

09/19/2025

“I've been evaluating anti-PAD antibodies in research settings, and I think they have a role in improving diagnosis and prognosis in RA, as well as a role in helping us to understand the biology of RA development. I'm happy to see anti-PAD antibodies becoming available for clinical testing in the USA to help improve the diagnosis of RA."

Kevin Deane, MD
Professor and Rheumatologist at the University of Colorado Denver School of Medicine

Learn more about Exagen’s newest biomarkers, anti-PAD4 IgA and IgG: https://avisetest.com/provider/avise-ra/

09/12/2025

Peptidylarginine deiminases (PADs) play a crucial role in the production of citrullinated proteins, the hallmark autoantigens of Rheumatoid Arthritis (RA). Anti-PAD4 autoantibodies target a key enzyme involved in the citrullination process.

Unlike traditional biomarkers, anti-PAD4 can be present in patients who are seronegative for RF and anti-CCP, helping clinicians identify RA earlier in the disease course. By providing additional diagnostic and prognostic insight, anti-PAD4 supports earlier intervention and greater confidence when differentiating RA from other inflammatory arthritides, especially in clinically ambiguous cases.

Learn more about Exagen’s newest biomarkers: https://avisetest.com/provider/avise-ra/

09/08/2025

Peptidylarginine deiminases (PADs) play a crucial role in the production of citrullinated proteins, the hallmark autoantigens of Rheumatoid Arthritis (RA). Anti-PAD4 autoantibodies target a key enzyme involved in the citrullination process.
We're excited to announce the addition of two new innovative seronegative rheumatoid arthritis (RA) biomarkers, anti-PAD4 IgG and IgA, now included with every AVISE® CTD test.

With up to 30% of RA patients testing negative for conventional biomarkers anti-CCP and rheumatoid factor, anti-PAD4 biomarkers provide greater diagnostic sensitivity. This allows clinicians to identify seronegative RA earlier, enhance diagnostic clarity, and gain valuable prognostic insights to help guide clinical decision-making.

Available starting today.

Learn more: https://avisetest.com/provider/avise-ra/

08/19/2025

Don’t forget to register for our upcoming webinar on innovative and comprehensive serological testing in autoimmune disease diagnostics. Learn how AVISE® CTD is helping improve diagnostic accuracy and patient outcomes—secure your spot today.

https://xtalks.com/webinars/beyond-diagnosis-the-real-world-impact-of-avise-testing-on-lupus-rheumatoid-arthritis-and-autoimmune-disease-care/

08/14/2025

Join our webinar to learn how innovative serological testing is transforming diagnostic accuracy for , , and other connective tissue diseases. Gain practical insights through real-world case studies, and learn how enhanced diagnostics via AVISE® CTD are improving patient outcomes and streamlining clinical practice —register now!

https://xtalks.com/webinars/beyond-diagnosis-the-real-world-impact-of-avise-testing-on-lupus-rheumatoid-arthritis-and-autoimmune-disease-care/

05/30/2025

A huge thank you to everyone who participated in our "Give for Lupus" blood drive with the American Red Cross and helped spread awareness all month long. Your support means everything—and we’re proud to stand together in the fight against lupus. Let’s keep the momentum going—because raising awareness and supporting those impacted by lupus is a year-round commitment.

Address

1261 Liberty Way
Vista, CA
92081

Telephone

+18884521522

Website

http://www.exagen.com/

Alerts

Be the first to know and let us send you an email when Exagen posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Exagen:

Shortcuts

Want your practice to be the top-listed Clinic in Vista?